Viridian Therapeutics, Inc. VRDN Business Segments — Segment research and development expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept vrdn:ResearchAndDevelopmentExpenseExcludingShareBasedCompensationExpense.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s business segments — segment research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s business segments — segment research and development expense?
- Viridian Therapeutics, Inc. (VRDN) reported business segments — segment research and development expense of $71.74M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s business segments — segment research and development expense changed year-over-year?
- Viridian Therapeutics, Inc.'s business segments — segment research and development expense increased by 1.0% year-over-year, from $71.04M to $71.74M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s business segments — segment research and development expense?
- Over 3 years (2022 to 2025), Viridian Therapeutics, Inc.'s business segments — segment research and development expense has grown at a 50.2% compound annual growth rate (CAGR), from $93.6M to $317.22M.
- What does business segments — segment research and development expense mean?
- This metric represents the total costs incurred by the business segment for research and development activities, including clinical trials and drug candidate advancement. It reflects the company's investment in innovation and the pipeline development necessary to bring therapeutic products to market. High levels of expenditure in this category are typical for clinical-stage biopharmaceutical companies focused on long-term product commercialization.